Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
224.9 USD | +2.21% | +3.27% | -13.07% |
May. 31 | Biogen: Brussels grants marketing authorization for Charcot disease | CF |
May. 31 | Disaster averted |
Evolution of the average Target Price on Biogen Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Biogen Inc.
Wedbush | |
Argus | |
Redburn Atlantic | |
HSBC | |
Guggenheim | |
HC Wainwright | |
Barclays | |
Canaccord Genuity | |
Goldman Sachs | |
Morgan Stanley | |
Piper Sandler | |
RBC Capital Markets | |
Needham & Co. | |
BMO Capital | |
Oppenheimer | |
UBS | |
JPMorgan Chase | |
Stifel Nicolaus | |
TD Cowen | |
Scotiabank | |
Baird | |
Wells Fargo Securities | |
BofA Securities | |
Raymond James | |
Mizuho Securities | |
Atlantic Equities | |
Jefferies & Co. | |
Truist Securities | |
Cowen | |
SVB Securities LLC | |
SVB Leerink | |
Cantor Fitzgerald | |
Bernstein | |
William Blair & Co. | |
Citigroup | |
Credit Suisse | |
DZ Bank |
EPS Revisions
- Stock Market
- Equities
- BIIB Stock
- Consensus Biogen Inc.